



FRANKLIN TEMPLETON GLOBAL  
FUNDS PLC  
20-26 Sir John Rogerson's Quay  
Grand Canal Dock  
Dublin 2  
D02 Y049  
Ireland

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF YOU ARE IN ANY DOUBT AS TO THE ACTION YOU SHOULD TAKE, YOU SHOULD SEEK INDEPENDENT PROFESSIONAL ADVICE.

This is not a proxy form and as such does not require you to vote. If you have sold or transferred all of your shares in Franklin Templeton Global Funds plc (the "Company"), please pass this document to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

Unless otherwise defined in this document, all capitalised terms have the same meaning as capitalised terms used in the Company's latest Irish prospectus (the "Prospectus") and the Hong Kong Covering Document. Copies of the Prospectus, the Hong Kong Covering Document and the Product Key Facts Statements of all SFC-authorized Funds<sup>1</sup> (together the "Hong Kong Offering Documents") as well as the Articles of Association and the latest annual and semi-annual reports of the Company are available upon request during normal business hours from your distributor or the Hong Kong Representative. The latest Hong Kong Offering Documents are also available at <http://www.franklintempleton.com.hk><sup>2</sup>.

Please note that the Central Bank of Ireland (the "Central Bank") has not reviewed this letter. The Directors accept responsibility for the accuracy of the information contained in this letter and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement in this letter misleading.

Hong Kong, 7 April 2026

## Amendments to the Hong Kong Offering Documents

Dear Shareholder,

We would like to let you know that the Directors decided to approve amendments to certain sub-funds of the Company (the "**Sub-Funds**"). A list of the Sub-Funds being updated is set out in Appendix A of this letter. Details of the more significant amendments being made are listed in Appendix B of this letter. Where updates are being made and are not included in Appendix B, they are deemed less material. You are advised to view the redlines illustrating the full suite of amendments being made to the Prospectus and the Supplements of certain Sub-Funds, including those that are not deemed to be significant, at the following link: <https://franklintempletonprod.widen.net/s/6khjrsrx27/redlines-ftgf-irish-pro-and-fund-supplements-en><sup>2</sup> (*English version*) and <https://franklintempletonprod.widen.net/s/tzpjxfvc/redlines-ftgf-irish-pro-and-fund-supplements-cn><sup>2</sup> (*Chinese version*).

<sup>1</sup> The authorisation by the Securities and Futures Commission of Hong Kong (the "**SFC**") is not a recommendation or endorsement of the Company or the SFC-authorized Funds nor does it guarantee the commercial merits of an SFC-authorized Fund or its performance. It does not mean an SFC-authorized Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

<sup>2</sup> This website has not been reviewed by the SFC.

Franklin Templeton Global Funds plc

Registered Office: as above

Company Registration Number: 278601

An umbrella fund with segregated liability between sub-funds

Registered in Ireland: Regulated by the Central Bank of Ireland

Directors: Joseph Carrier (U.S.A.), Fionnuala Doris, Joseph Keane, Joseph LaRocque (U.S.A), Elinor Murray (U.K.), Jaspal Sagger (U.K.), Craig Tyle (U.S.A)

The amendments to the Prospectus and the Supplements of the Sub-Funds will take effect on the date on which the revised Prospectus and the revised Supplements of the Sub-Funds are approved by the Central Bank (the “**Effective Date**”). The Effective Date will be on or around 20 May 2026. The Hong Kong Offering Documents will be updated to reflect the changes as set out herein, as well as other miscellaneous updates, drafting and/or editorial amendments, on or after the Effective Date.


### **What you need to do**

You do not need to do anything if you are satisfied with the changes. If you do not wish to remain in the Sub-Funds following the implementation of the changes as set out herein, you may switch your shares into other SFC-authorized<sup>1</sup> sub-funds of the Company or redeem your shares by following the usual procedures as set out in the Hong Kong Offering Documents. Requests of switch or redemption will be executed free of charge. However, if you deal via any bank, relevant distributor or financial adviser, such entity may charge you transaction or adviser fees (as the case may be) in respect of any such request.

### **Need more information?**

Should you have any questions relating to these matters, please contact your Franklin Templeton Representative. Alternatively, you may speak to your financial advisor, your distributor or the Hong Kong Representative at 62/F, Two International Finance Centre, 8 Finance Street, Central, Hong Kong (Investor hotline: +852 2805 0111) as appropriate.

Yours sincerely,



Director  
For and behalf of  
Franklin Templeton Global Funds plc

**Appendix A**

**List of Sub-Funds being updated (material and immaterial updates)**

*You are advised to view the redlines illustrating the full suite of amendments being made to the Prospectus and the Supplements of certain Sub-Funds, including those that are not deemed to be significant, at the following link:*

<https://franklintempletonprod.widen.net/s/6khjrsrx27/redlines-ftgf-irish-pro-and-fund-supplements-en><sup>2</sup> (English version) and <https://franklintempletonprod.widen.net/s/tzpjkfxfvc/redlines-ftgf-irish-pro-and-fund-supplements-cn><sup>2</sup> (Chinese version).

FTGF Brandywine Global Fixed Income Fund  
FTGF Brandywine Global Income Optimiser Fund  
FTGF ClearBridge Global Growth Leaders Fund  
FTGF ClearBridge Global Infrastructure Income Fund  
FTGF ClearBridge Tactical Dividend Income Fund  
FTGF ClearBridge US Aggressive Growth Fund  
FTGF ClearBridge US Equity Sustainability Leaders Fund  
FTGF ClearBridge US Large Cap Growth Fund  
FTGF ClearBridge US Value Fund  
FTGF Putnam Global Healthcare Fund

FTGF Putnam US Research Fund  
FTGF Royce US Smaller Companies Fund  
FTGF Western Asset Global High Yield Fund  
FTGF Western Asset Global Multi Strategy Fund  
FTGF Western Asset Short Duration Blue Chip Bond Fund  
FTGF Western Asset US Core Bond Fund  
FTGF Western Asset US Core Plus Bond Fund  
FTGF Western Asset US Government Liquidity Fund  
FTGF Western Asset US High Yield Fund

## Appendix B

### Notable Changes

As noted above, redlines illustrating the full suite of amendments are available, for your inspection, at <https://franklintempletonprod.widen.net/s/6khjrsrx27/redlines-ftgf-irish-pro-and-fund-supplements-en><sup>2</sup> (*English version*) and <https://franklintempletonprod.widen.net/s/tzpjkfxfvc/redlines-ftgf-irish-pro-and-fund-supplements-cn><sup>2</sup> (*Chinese version*). If your sub-fund is listed in Appendix A but not included in Appendix B, you will find the updates in this link.

#### Notable Changes to the Prospectus

To benefit investors by facilitating subscription flows and fostering the growth of the relevant Sub-Funds, the Directors have decided to update the disclosure relating to the dilution adjustments. The revised language will clarify that the consideration will be given to the application of swing pricing on subscriptions for Sub-Funds that are in an early life cycle or growth phase and where assets are not yet reached an optimal scale.

Save for the changes described above, no other amendments will be made to the swing pricing mechanism (including the current swing factor of 2% as disclosed in the Prospectus). The changes will not negatively impact the liquidity management of the Sub-Funds, and there will be no material change to the features and risks applicable to the Sub-Funds following the changes. In addition, there will be no change to the operation and/or manner in which the Sub-Funds are being managed and there are no other impacts on existing shareholders. The changes will not give rise to any change in the fee level or cost in managing the Sub-Funds, and it will not materially prejudice the rights or interests of existing shareholders of the Sub-Funds.

#### Notable Changes to the Supplements of certain Sub-Funds

Sub-Fund	Change	Rationale
<b>FTGF Royce US Smaller Companies Fund</b>	Reclassification from an existing Article 6 classification to an Article 8 classification under the Sustainable Finance Disclosure Regulation ((EU) 2019/2088) (“ <b>SFDR</b> ”). The Supplement of the Sub-Fund is being updated to reflect the necessary Article 8 disclosures as well as to make ancillary updates to the environmental, social and governance (“ <b>ESG</b> ”) investment process.	The reclassification and ancillary disclosure updates which are being introduced are being made to better align the SFDR categorisation with how the Sub-Fund is already managed.
<b>FTGF ClearBridge US Large Cap Growth Fund</b>	To remove the following exclusion, which is listed as a binding element of the investment strategy: <i>“companies that generate 10% or more of their turnover directly from conventional weapons.”</i>	The Sub-Fund’s binding criteria are being updated to align with evolving industry criteria for assessing exposure to “military hardware” which, in certain markets, can now be determined based

		solely on whether an issuer generates turnover from controversial weapons.
<b>FTGF Western Aset US Government Liquidity Fund</b>	<p>i. To reduce the minimum allocation to Public Debt Money Market Instruments denominated in US Dollars and issued by US issuers from two-thirds of the Sub-Fund's Net Asset Value to 50% of the Sub-Fund's Net Asset Value.</p> <p>ii. To remove the initial sales charge of up to 5% applied to Class A Shares and up to 2.5 applied to Class E Shares. For the avoidance of doubt, Class E Shares are not available to the public in Hong Kong.</p>	<p>i. This is a clarificatory change that will not change how the Sub-Fund is managed, nor will it affect the Sub-Fund's risk profile.</p> <p>ii. These charges are not typically applied in practice given the nature of the Sub-Fund, so this is intended to be a clarificatory change.</p>
<b>FTGF Putnam US Research Fund</b>	<p>i. To amend the asset allocation guidelines by adjusting the percentage of holdings aligned with Environmental and/or Social characteristics from 95% to 80% in bucket #1 and increasing bucket #2 from 5% to 20%. Additionally, to disclose that bucket #2 may include certain ETF investments not aligned with Environmental and/or Social characteristics.</p> <p>ii. Update the disclosure of sustainability indicators to include additional detail in the disclosure on UN Global Compact compliance monitoring, the Low Carbon Intensity metric, Sustainalytics ESG Risk Rating category bands, and the exclusion indicator reflecting the Sub-Fund's exclusion policy.</p> <p>iii. Update the disclosure of promoted characteristics to include additional detail in the disclosure on UN Global Compact compliance, the Low Carbon Intensity metric, Sustainalytics ESG Risk Rating category bands, and the exclusion indicator reflecting the Sub-Fund's exclusion policy.</p>	<p>i. The change enables the use of ETFs within the portfolios and includes a corresponding reallocation of assets, with a reduction in bucket #1 and an increase in the "#2 Other" bucket to reflect the inclusion of certain ETF investments alongside cash, cash equivalents, and derivatives.</p> <p>ii. This is a clarificatory change that will not change how the Sub-Fund is managed.</p> <p>iii. This is a clarificatory change that will not change how the Sub-Fund is managed.</p>

	<p>To introduce a 20% Minimum Sustainable Investment allocation for the Sub-Fund, with minimum thresholds of Min E: 1% and Min S: 1%, to be applied in accordance with the following Sustainable Investment methodology:</p> <ul style="list-style-type: none"> <li>- Contribution to an E and/or S objective if: <ul style="list-style-type: none"> <li>- &gt; 20% revenue from activities that align with environmental and/or social impact themes (climate action, human development, basic needs, resource security, healthy ecosystems) as determined by a third-party data provider; or</li> <li>- Contributing to an environmental objective by gaining and maintaining Science Based Target Initiative (SBTi) approved GHG emissions reduction targets or equivalent and are thus considered as contributing to fighting against climate change.</li> </ul> </li> <li>- DNSH: <ul style="list-style-type: none"> <li>- Must pass the investment manager's PAI consideration thresholds. PAI considerations are embedded into Putnam's fundamental research and correlated to the proprietary ESG materiality framework.</li> </ul> </li> <li>- Good Governance <ul style="list-style-type: none"> <li>- No service risk controversy score</li> <li>- Must pass third-party global norms-based screening for UN Global Compact (UNGC) compliance</li> <li>- Must pass Putnam proprietary governance screen that incorporates third party risk ratings.</li> </ul> </li> </ul>	<p>The introduction of a minimum sustainable investment commitment is intended to support consistent and clear disclosure of the Sub-Fund's sustainable investment allocations. This change enables the Sub-Fund to align with market and investor expectations without altering the underlying investment process or portfolio construction.</p>
<b>FTGF Putnam Global Healthcare Fund</b>	<p>To amend the asset allocation percentage of holdings aligned with Environmental and/or Social characteristics from 90% to 80% in bucket #1, update bucket #2 from 10% to 20%, and disclose</p>	<p>The change enables the use of ETFs within the portfolios and includes a corresponding reallocation of assets, with a reduction in bucket #1 and an increase in the "#2 Other" bucket to</p>

	that bucket #2 may include certain ETF investments not aligned with Environmental and/or Social characteristics.	reflect the inclusion of certain ETF investments alongside cash, cash equivalents, and derivatives.
<b>FTGF Putnam US Research Fund</b> <b>FTGF Putnam Global Healthcare Fund</b>	<p>Update and align the ‘What is the asset allocation planned for this financial product?’ and ‘What investments are included under “#2 Other” [#2 Not sustainable] sections to clarify derivative usage as shown below:</p> <p>Question: <i>‘What is the asset allocation planned for this financial product?’</i> The Investment Manager employs a binding proprietary ESG methodology which is applied to at least ≥80% of the Sub-Fund’s portfolio. The remaining portion (≤20%%) of the portfolio is not aligned with the promoted characteristics and consists of cash held on deposit, cash equivalents, derivative instruments (used for investment, efficient portfolio management and/or hedging purposes) and certain ETF investments.</p> <p>Question: <i>‘What investments are included under “#2 Other” [#2 Not sustainable], what is their purpose and are there any minimum environmental or social safeguards?’</i> #2 Other comprises cash held on deposit, cash equivalents and derivative instruments (used for investment, efficient portfolio management and/or hedging purposes) and certain ETFs for which there are no minimum environmental or social safeguards.</p>	This is a clarificatory change to ensure alignment between the Sub-Funds and bucket #2 so there is consistency. There will be no impact to the portfolio.
<b>All</b>	In line with the UCITS VI Directive and the related Level 2 regulatory technical standards, the Prospectus will be updated to include enhanced disclosures on the liquidity management tools that may be available to the Sub-Funds of the Company. The updates are intended to enhance	These changes are disclosure-based only and do not alter the investment objective or investment policy of any Sub-Fund.

	transparency and investor understanding in line with evolving regulatory requirements.	
<b>FTGF Brandywine Global Fixed Income Fund</b> <b>FTGF ClearBridge Global Growth Leaders Fund</b> <b>FTGF Putnam US Research Fund</b> <b>FTGF ClearBridge US Large Cap Growth Fund</b> <b>FTGF Royce US Small Cap Opportunity Fund</b> <b>FTGF Western Asset Global Multi Strategy Fund</b> <b>FTGF Western Asset US Core Plus Bond Fund</b>	<p>To lower the maximum contingent deferred sales charge ("CDSC") for Class B Shares from 5% to 4% and reduce the duration of the CDSC schedule from 5 years to 4 years.</p> <p>For the avoidance of doubt, Class B Shares are not available for offering to the public in Hong Kong.</p>	To align the maximum CDSC with the applicable rate of 4% and make the corresponding update to align the duration of the CDSC schedule.